New cell therapy TAK-007 tested in lymphoma patients who have run out of options
NCT ID NCT05020015
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing an experimental cell therapy called TAK-007 in 27 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. Participants first receive chemotherapy to lower certain white blood cells, then get one or three injections of TAK-007. The study is checking for side effects and whether the lymphoma shrinks or disappears.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TAK-007 (a cell therapy) given as an injection after chemotherapy
What this could lead to
If successful, this could offer a new treatment option for people with B-cell non-Hodgkin lymphoma that has not responded to other therapies.
What could go wrong
This is a small, early-phase trial with only 27 participants, so results may not apply to everyone. Side effects from the cell therapy or chemotherapy could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (NHL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
Los Angeles, California, 90048, United States
-
Columbia University Medical Center
New York, New York, 10032, United States
-
DUHS Duke Blood Cancer Center
Durham, North Carolina, 27705, United States
-
MedStar Georgetown University Medical Center
Washington D.C., District of Columbia, 20007, United States
-
Montefiore Medical Center
The Bronx, New York, 10467, United States
-
Northside Hospital
Atlanta, Georgia, 30342, United States
-
Northwestern Memorial Hospital
Chicago, Illinois, 60611, United States
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
Saint Davids South Austin Medical Center
Austin, Texas, 78704, United States
-
Sylvester Comprehensive Cancer Center University of Miami Hospitals and Clinics
Miami, Florida, 33136, United States
-
Thomas Jefferson University Sidney Kimmer Cancer Center, Clinical Research Organization
Philadelphia, Pennsylvania, 19107, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35249, United States
-
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia, 22903, United States